Vericel Corporation (VCEL)

From the record

Vericel Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Vericel Corporation's 10 filed years say what it did: revenue went from $54 million in fiscal 2016 to $276 million in fiscal 2025, up 19.8% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Vericel Corporation's diluted share count grew about 3.4% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 44 sales (40 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Vericel Corporation earned about 5 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 42 cents per dollar of everything the company owns. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).

From the record

Vericel Corporation's standing among 102 graded names in its industry family: revenue of $276 million in fiscal 2025 ranks in the top 19% by size; a net margin of 6% ranks in the top 19%; revenue growth of 18.9% a year over the last 3 filed years ranks in the top 36% (its annual reports).

From the record

Vericel Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Colangelo, Dominick (President and CEO, as filed), filing under that title since 2013-03-08, 13.7 years (top 4% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 7.4 years (top 18%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 3%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Vericel Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $100 million against no long-term debt tagged leaves 20.5% of its assets as net cash, bottom 41% of its family; cash from operations less capital spending is 9% of revenue (top 17%); a gross margin of 74.4% (top 44%); research spending of 10% of revenue (bottom 8%) (its annual report).

From the record

Vericel Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 18.9% a year over the last three filed years against 19.8% over all 10, slowing (top 45% of its family); the newest year grew 16.5% (top 49%); research spending grew 11.4% a year (top 29%); capital spending grew 52.9% a year (top 7%) (its annual reports). Vericel Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Vericel Corporation's newest year against its own record: revenue of $276 million in fiscal 2025 came in 3.1% below the $285 million its prior three years' pace pointed to (bottom 42% of its family); net income of $17 million against a prior three-year average of $3 million (top 1%); a net margin of 6% against -2.5% before (bottom 42%) (its annual reports).